May 9
SNDX · Syndax Pharmaceuticals Inc · Documents
$8.72
-0.41 (-4.49%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$778.67M
Shares
89.30M
Volume · Nov 20
2.18M
Avg daily vol (3M)
2.61M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2022
Mar 30
Proxy statement
DEFA14A
Proxy statement
Mar 29
Proxy statement
DEF 14A
Meeting May 11, 2022
Proxy statement
Mar 1
Earnings call
Q4 2021 earnings call
Mar 1
Mar 1
Annual report
10-K
FY2021, ended Dec 31
Annual report for FY2021
Revenue $139.71M
▲ 9109.6%
Net income $24.93M
Diluted EPS $0.46
Feb 24
Current report
8-K
Events of Feb 22
Director or officer change, or executive pay
Feb 3
Current report
8-K
Events of Feb 2
Director or officer change, or executive pay, Regulation FD disclosure
2021
Dec 23
Current report
8-K
Events of Dec 22
Entered into a material agreement, New debt or off-balance-sheet obligation
Dec 17
Current report
8-K
Events of Dec 15
Entered into a material agreement
Dec 13
Current report
8-K
Events of Dec 11
Other events
Dec 9
Current report
8-K
Other events
Nov 15
Earnings call
Q3 2021 earnings call
Nov 15
Current report
8-K
Financial results
Nov 15
Quarterly report
10-Q
FY2021 Q3, ended Sep 30
Quarterly report for FY2021 Q3
Revenue $12.38M
▲ 3165.2%
Net loss $20.64M
Oct 4
Current report
8-K
Director or officer change, or executive pay
Sep 27
Current report
8-K
Events of Sep 24
Entered into a material agreement, Regulation FD disclosure
Sep 15
Current report
8-K
Director or officer change, or executive pay
Aug 9
Earnings call
Q2 2021 earnings call
Aug 9
Current report
8-K
Financial results
Aug 9
Quarterly report
10-Q
FY2021 Q2, ended Jun 30
Quarterly report for FY2021 Q2
Revenue $379K
▲ unchanged
Net loss $22.91M
May 13
Current report
8-K
Shareholder vote results
May 11
Earnings call
Q1 2021 earnings call
May 11
Current report
8-K
Financial results
May 11
Quarterly report
10-Q
FY2021 Q1, ended Mar 31
Quarterly report for FY2021 Q1
Revenue $379K
▲ unchanged
Net loss $27.72M
Apr 30
Annual report
10-K/A
Ended Dec 31
Annual report for the period ended Dec 31, 2020
Apr 1
Proxy statement
DEF 14A
Meeting May 13, 2021
Proxy statement
Mar 24
Registration statement
S-3ASR
Registration statement
Mar 22
Registration statement
S-3
Registration statement
Mar 12
Annual report
10-K
FY2020, ended Dec 31
Annual report for FY2020
Revenue $1.52M
▲ unchanged
Net loss $73.16M
Mar 8
Earnings call
Q4 2020 earnings call
Mar 8
Current report
8-K
Financial results
Feb 5
Current report
8-K
Events of Feb 3
Director or officer change, or executive pay
2020
Dec 9
Current report
8-K
Events of Dec 8
Entered into a material agreement
Dec 7
Current report
8-K
Ended a material agreement, Other events
Nov 5
Quarterly report
10-Q
FY2020 Q3, ended Sep 30
Quarterly report for FY2020 Q3
Revenue $379K
▲ unchanged
Net loss $20.44M
Nov 2
Earnings call
Q3 2020 earnings call
Nov 2
Current report
8-K
Financial results
Aug 6
Earnings call
Q2 2020 earnings call
Aug 6
Current report
8-K
Financial results
Aug 6
Quarterly report
10-Q
FY2020 Q2, ended Jun 30
Quarterly report for FY2020 Q2
Revenue $379K
▲ unchanged
Net loss $17.06M
Jul 7
Current report
8-K
Events of Jul 6
Director or officer change, or executive pay
Jun 9
Current report
8-K
Shareholder vote results
May 7
Current report
8-K
Financial results
May 7
Quarterly report
10-Q
FY2020 Q1, ended Mar 31
Quarterly report for FY2020 Q1
Revenue $379K
▲ unchanged
Net loss $15.24M
May 4
Current report
8-K
Events of Apr 30
Entered into a material agreement, Other events
Apr 30
Earnings call
Q1 2020 earnings call
Apr 30
Current report
8-K
Financial results, Other events
Apr 29
Proxy statement
DEF 14A
Meeting Jun 9, 2020
Proxy statement
Mar 5
Annual report
10-K
FY2019, ended Dec 31
Annual report for FY2019
Revenue $1.52M
▲ unchanged
Net loss $56.05M
Showing 101–150 of 154 documents
Key facts
CIK
1395937
CUSIP
87164F105
13F (30d)
241 filings
222 filers
Visit website
Investor relations